Early ultrasound for diagnosis and treatment of vascular adverse events with hyaluronic acid fillers.


Journal

Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132

Informations de publication

Date de publication:
01 2023
Historique:
received: 06 05 2019
revised: 05 07 2019
accepted: 11 07 2019
pubmed: 22 7 2019
medline: 21 12 2022
entrez: 21 7 2019
Statut: ppublish

Résumé

Hyaluronic acid fillers are known for a reliable safety profile, but complications do occur, even serious vascular adverse events. To improve the treatment outcome after a vascular adverse event with use of hyaluronic acid filler treatments. Duplex ultrasonography is used to detect the hyaluronic acid filler causing the intra-arterial obstruction. If treated in time, 1 single treatment of ultrasonographically guided injections of hyaluronidase into the filler deposit will prevent skin necrosis. Because the use of duplex ultrasonography adds extra essential information, its use may become an integral part of the prevention and treatment of injection adverse events.

Sections du résumé

BACKGROUND
Hyaluronic acid fillers are known for a reliable safety profile, but complications do occur, even serious vascular adverse events.
OBJECTIVE
To improve the treatment outcome after a vascular adverse event with use of hyaluronic acid filler treatments.
METHODS
Duplex ultrasonography is used to detect the hyaluronic acid filler causing the intra-arterial obstruction.
RESULTS
If treated in time, 1 single treatment of ultrasonographically guided injections of hyaluronidase into the filler deposit will prevent skin necrosis.
CONCLUSION
Because the use of duplex ultrasonography adds extra essential information, its use may become an integral part of the prevention and treatment of injection adverse events.

Identifiants

pubmed: 31325548
pii: S0190-9622(19)32392-8
doi: 10.1016/j.jaad.2019.07.032
pii:
doi:

Substances chimiques

Dermal Fillers 0
Hyaluronic Acid 9004-61-9
Hyaluronoglucosaminidase EC 3.2.1.35

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-85

Informations de copyright

Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Auteurs

Leonie W Schelke (LW)

Erasmus Medical Centre, Department of Dermatology, Rotterdam, The Netherlands. Electronic address: lschelke@outlook.com.

Peter Velthuis (P)

ReSculpt Clinic, Department of Dermatology, Amsterdam, The Netherlands.

Jonathan Kadouch (J)

ReSculpt Clinic, Department of Dermatology, Amsterdam, The Netherlands.

Arthur Swift (A)

Westmount Institute of Plastic Surgery, Montreal, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH